SWM
GBT

Spire Wealth Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Spire Wealth Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-135
Closed -$4K – 2983
2021
Q4 		$4K Buy
+135
New +$4.18K ﹤0.01% 2665
2021
Q3 		– Sell
-40
Closed -$1K – 2680
2021
Q2 		$1K Hold
40
– – ﹤0.01% 2560
2021
Q1 		$2K Buy
+40
New +$1.84K ﹤0.01% 2908

Other funds holding GBT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Spire Wealth Management's GBT Position: Q1 2022 in Review

Spire Wealth Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q1 2022, closing a stake of 135 shares — an estimated $4K sold.

Spire Wealth Management first reported a position in GBT in Q1 2021 and held it in 3 quarters. The position peaked at $4K in Q4 2021. 204 funds tracked by Wall St. Rank hold GBT as of Q1 2022.

  • Spire Wealth Management reported no remaining Global Blood Therapeutics, Inc. position as of Q1 2022 after selling out during the quarter.
  • Spire Wealth Management sold 135 Global Blood Therapeutics, Inc. shares in Q1 2022, an estimated $4K.
  • Spire Wealth Management first reported a position in Global Blood Therapeutics, Inc. in Q1 2021 and held it in 3 quarters.
  • Spire Wealth Management's Global Blood Therapeutics, Inc. position peaked at $4K in Q4 2021.
  • 204 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q1 2022.

Based on Spire Wealth Management's 13F filing for Q1 2022, filed 18 Apr 2022.